This wiki has undergone a migration to Confluence found Here
Difference between revisions of "BiologicallyDerivedProduct FHIR Resource Proposal"
Jump to navigation
Jump to search
Kirt Schaper (talk | contribs) |
Kirt Schaper (talk | contribs) |
||
| Line 56: | Line 56: | ||
As a rule, resources should encompass all of these aspects. | As a rule, resources should encompass all of these aspects. | ||
--> | --> | ||
| − | + | A material substance originating from a biological entity intended to be transplanted or infused | |
| + | into another (possibly the same) biological entity. | ||
| + | |||
| + | Examples include: | ||
| + | * hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction) | ||
* blood (whole, extracted cells, plasma, etc) | * blood (whole, extracted cells, plasma, etc) | ||
| − | |||
* organs | * organs | ||
* tissues (porcine valves, skin, bovine cardiac tissue, etc.) | * tissues (porcine valves, skin, bovine cardiac tissue, etc.) | ||
Revision as of 22:32, 9 September 2017
This page documents a Pending FHIR Resource Proposal
Contents
- 1 BiologicallyDerivedProduct
- 1.1 Owning committee name
- 1.2 Committee Approval Date:
- 1.3 Contributing or Reviewing Work Groups
- 1.4 FHIR Resource Development Project Insight ID
- 1.5 Scope of coverage
- 1.6 RIM scope
- 1.7 Resource appropriateness
- 1.8 Expected implementations
- 1.9 Content sources
- 1.10 Resource Relationships
- 1.11 Timelines
- 1.12 gForge Users
- 1.13 When Resource Proposal Is Complete
- 1.14 FMG Notes
BiologicallyDerivedProduct
Owning committee name
Committee Approval Date:
Please enter the date that the committee approved this Resource proposal
Contributing or Reviewing Work Groups
- Orders and Observations
- Pharmacy
FHIR Resource Development Project Insight ID
Scope of coverage
A material substance originating from a biological entity intended to be transplanted or infused into another (possibly the same) biological entity.
Examples include:
- hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
- blood (whole, extracted cells, plasma, etc)
- organs
- tissues (porcine valves, skin, bovine cardiac tissue, etc.)
- manipulated cells (e.g. CAR T-cells)
RIM scope
Resource appropriateness
Expected implementations
Content sources
- Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct
- Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person
- Patient receives post-HCT infusion of donor t-cells
- Patient receives blood (BiologicallyDerivedProduct) transfusion
- Patient receives HLA-matched platelets (BiologicallyDerivedProduct)
- Patient receives heart transplant
- Patient undergoes cardiac surgery receiving pig heart valve
Resource Relationships
Timelines
gForge Users
When Resource Proposal Is Complete
When you have completed your proposal, please send an email to FMGcontact@HL7.org
